Rascase Rasburicase 1.5mg Injection

Rascase Rasburicase 1.5mg Injection is a specialised pharmaceutical product used to manage elevated uric acid levels in patients undergoing cancer treatment. It is commonly prescribed for conditions associated with tumour lysis syndrome, where rapid breakdown of cancer cells leads to increased uric acid in the blood. This injection helps reduce complications and supports safer chemotherapy management.

Formulated with Rasburicase as the active ingredient, this product works by converting uric acid into a more easily eliminated compound, helping maintain balanced uric acid levels. Rascase Rasburicase 1.5 mg Injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance.

Healthcare professionals widely recommend this pharmaceutical product for oncology care due to its fast-acting formulation and reliable results. The injection is administered under medical supervision and plays a critical role in improving patient support during intensive cancer therapy. Rascase Rasburicase 1.5 mg Injection stands out among oncology pharmaceutical products for its effectiveness, quality assurance, and contribution to better treatment outcomes in cancer management.

Product Features

• Fast-acting Rasburicase formulation for effective uric acid control
• Supports patients during intensive chemotherapy treatment
• High-quality pharmaceutical injection with reliable performance
• Helps reduce complications linked to tumor lysis syndrome
• Manufactured under strict quality and safety standards

How It Helps

• Helps reduce high uric acid levels quickly
• Supports patients undergoing chemotherapy treatment
• Assists in managing tumor lysis syndrome
• Improves patient safety during cancer therapy
• Promotes effective metabolic balance in the body